NasdaqGS - Nasdaq Real Time Price • USD
BioCryst Pharmaceuticals, Inc. (BCRX)
At close: April 24 at 4:00 PM EDT
After hours: April 24 at 7:31 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 11 | 11 | 11 | 10 |
| Avg. Estimate | -0.21 | -0.16 | -0.62 | -0.34 |
| Low Estimate | -0.28 | -0.32 | -0.84 | -0.76 |
| High Estimate | -0.14 | -0.06 | -0.26 | -0.11 |
| Year Ago EPS | -0.28 | -0.4 | -1.18 | -0.62 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 10 | 10 | 11 | 10 |
| Avg. Estimate | 85.8M | 98.08M | 394.99M | 475.7M |
| Low Estimate | 83.53M | 94.64M | 382.08M | 398M |
| High Estimate | 87.41M | 101.53M | 403.01M | 510.06M |
| Year Ago Sales | 68.78M | 82.49M | 331.41M | 394.99M |
| Sales Growth (year/est) | 24.70% | 18.90% | 19.20% | 20.40% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.3 | -0.23 | -0.23 | -0.24 |
| EPS Actual | -0.28 | -0.4 | -0.19 | -0.31 |
| Difference | 0.02 | -0.17 | 0.04 | -0.07 |
| Surprise % | 6.70% | -73.90% | 17.40% | -29.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.21 | -0.16 | -0.62 | -0.34 |
| 7 Days Ago | -0.21 | -0.16 | -0.62 | -0.34 |
| 30 Days Ago | -0.21 | -0.16 | -0.61 | -0.34 |
| 60 Days Ago | -0.22 | -0.16 | -0.72 | -0.39 |
| 90 Days Ago | -0.22 | -0.16 | -0.72 | -0.39 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | -- |
Growth Estimates
| CURRENCY IN USD | BCRX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 25.00% | -- | -- | 1.50% |
| Next Qtr. | 60.00% | -- | -- | 11.40% |
| Current Year | 47.50% | -- | -- | 5.20% |
| Next Year | 45.20% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 44.80% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Needham: Buy to Buy | 4/10/2024 |
| Reiterates | Needham: Buy to Buy | 1/8/2024 |
| Reiterates | Needham: Buy to Buy | 11/6/2023 |
| Reiterates | RBC Capital: Outperform to Outperform | 9/25/2023 |
| Upgrade | RBC Capital: Sector Perform to Outperform | 9/18/2023 |
| Maintains | RBC Capital: Sector Perform to Sector Perform | 8/4/2023 |
Related Tickers
TGTX TG Therapeutics, Inc.
13.98
-1.89%
AUPH Aurinia Pharmaceuticals Inc.
5.03
-1.18%
DAWN Day One Biopharmaceuticals, Inc.
15.19
-8.71%
GRTS Gritstone bio, Inc.
0.8129
+10.06%
SAGE Sage Therapeutics, Inc.
14.00
+8.11%
ARDX Ardelyx, Inc.
6.43
+0.63%
AGEN Agenus Inc.
7.42
+14.86%
ACAD ACADIA Pharmaceuticals Inc.
16.59
-0.90%
ABEO Abeona Therapeutics Inc.
3.1700
-7.04%
ADAP Adaptimmune Therapeutics plc
1.0800
-5.26%